New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... - PR-inside.com (press release)

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... PR-inside.com (press release) ACZ885 significantly reduced rate of acute flares up to 75% vs. anti-inflammatory colchicine in gout patients starting uric acid lowering therapy (UALT)[1] ... Novartis ACZ885 prevented acute flares in gout patiends shows studyFrontier India - News, Analysis, Opinion EULAR: Novel Agent Eases Gout PainMedPage Today all 8 news articles »

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint - BioWorld Online

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint BioWorld Online Colchicine currently is used to treat gout flares, but that drug is limited due to side effects. Many patients usually just end up going off all treatment. ... Shares of Regeneron Pharmaceuticals (REGN) Continue to Slide for Fifth ...StreetInsider.com (subscription) all 74 news articles »

Gout at the age of 15 - AsiaOne

AsiaOne

Gout at the age of 15 AsiaOne He was prescribed medication like allopurinol to control his uric acid levels and colchicine to stem the inflammation. At times, the medicine did not work ...

Regeneron's phase 3 trial for prevention of gout flares in patients initiating ... - pharmabiz.com

Regeneron's phase 3 trial for prevention of gout flares in patients initiating ... pharmabiz.com Anti-inflammatory therapy with colchicine is sometimes used to help prevent these flares. However, the side effects associated with colchicine, ... and more »